GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alpha Tau Medical Ltd (NAS:DRTS) » Definitions » Total Current Assets

DRTS (Alpha Tau Medical) Total Current Assets : $64.23 Mil (As of Dec. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Alpha Tau Medical Total Current Assets?

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. Alpha Tau Medical's total current assets for the quarter that ended in Dec. 2024 was $64.23 Mil.


Alpha Tau Medical Total Current Assets Historical Data

The historical data trend for Alpha Tau Medical's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alpha Tau Medical Total Current Assets Chart

Alpha Tau Medical Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Total Current Assets
Get a 7-Day Free Trial 47.46 32.64 106.48 85.76 64.23

Alpha Tau Medical Quarterly Data
Dec19 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Total Current Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 85.76 81.20 75.25 69.79 64.23

Alpha Tau Medical Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

Alpha Tau Medical's Total Current Assets for the fiscal year that ended in Dec. 2024 is calculated as

Alpha Tau Medical's Total Current Assets for the quarter that ended in Dec. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.


Alpha Tau Medical  (NAS:DRTS) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

Alpha Tau Medical's Liquidation Value for the quarter that ended in Dec. 2024 is

Liquidation value
= Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=59.6-23.538+0.75 * 0+0.5 * 0
=36.06

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Alpha Tau Medical Total Current Assets Related Terms

Thank you for viewing the detailed overview of Alpha Tau Medical's Total Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Alpha Tau Medical Business Description

Traded in Other Exchanges
N/A
Address
Kiryat Hamada Street 5, Jerusalem, ISR, 9777605
Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company derives maximum revenue from Israel.